Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160

Showing 51-75 of 160 citing articles:

Multimodal assessment of non-alcoholic fatty liver disease with transmission-reflection optoacoustic ultrasound
Berkan Lafci, Anna Hadjihambi, Madita Determann, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4217-4228
Open Access | Times Cited: 11
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
Iqra Mazhar, Mohamed Yasir, Saba Sarfraz, et al.
Cureus (2023)
Open Access | Times Cited: 10
Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis
H. J. Yang, Ying Zou, Jun Chen, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 10
Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota
Luping Chen, Linfang Zhang, Shuang Liu, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 3
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors and Prevention
Benedetta Maria Motta, Mario Masarone, Pietro Torre, et al.
(2023)
Open Access | Times Cited: 9
Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis
Omar E Hegazi, Samer O Alalalmeh, Moyad Shahwan, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 545-561
Open Access | Times Cited: 3
Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice
Akemi Ichikawa, Daiki Miki, C. Nelson Hayes, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Higher Adherence to Healthy Lifestyle Score Is Associated with Lower Odds of Non-Alcoholic Fatty Liver Disease
Yu Zhu, Yang Hu, Shaoxian Liang, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4462-4462
Open Access | Times Cited: 14
Beta-Caryophyllene Modifies Intracellular Lipid Composition in a Cell Model of Hepatic Steatosis by Acting through CB2 and PPAR Receptors
Rosaria Scandiffio, Sara Bonzano, Erika Cottone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6060-6060
Open Access | Times Cited: 8
Intermittent fasting activates macrophage migration inhibitory factor and alleviates high-fat diet-induced nonalcoholic fatty liver disease
Dezhao Li, Yaoshan Dun, Dake Qi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Hypersampones A–C, Three Nor-Polycyclic Polyprenylated Acylphloroglucinols with Lipid-Lowering Activity from Hypericum sampsonii
Lei Huang, Zizhen Zhang, Yanan Li, et al.
Organic Letters (2022) Vol. 24, Iss. 32, pp. 5967-5971
Closed Access | Times Cited: 13
Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway
Jie Yu, Yuan Zhao, Lingling Xu, et al.
Mediators of Inflammation (2023) Vol. 2023, pp. 1-12
Open Access | Times Cited: 7
Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta‐analysis of randomized controlled trials
Ali Ardekani, Reza Tabrizi, Elham Maleki, et al.
Food Science & Nutrition (2023) Vol. 11, Iss. 6, pp. 2580-2588
Open Access | Times Cited: 7
SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
K.M. PRASANNA KUMAR, Ambika Gopalakrishnan Unnikrishnan, Pankaj Jariwala, et al.
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 1, pp. 11-18
Open Access | Times Cited: 2
Association between dietary carbohydrate to fiber ratio and metabolic dysfunction associated fatty liver disease in adults: evidence from the NHANES 2017–2020
Zhenmin Liu, Taiyong Fang
Journal of Health Population and Nutrition (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Inhibitory effect of ultrasonicated sesame meal on fat accumulation of 3T3-L1 adipocytes and oleic acid induced HepG2 hepatocytes
Ji‐Eun Kim, Ji-Yun Bae, Mi‐Ja Kim
Journal of Functional Foods (2024) Vol. 117, pp. 106239-106239
Open Access | Times Cited: 2
Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction‐associated steatotic liver disease: A systematic review
Basile Njei, Yazan A. Al‐Ajlouni, Prince A. Ameyaw, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 9, pp. 1788-1808
Closed Access | Times Cited: 2
From petals to healing: consolidated network pharmacology and molecular docking investigations of the mechanisms underpinning Rhododendron arboreum flower’s anti-NAFLD effects
Nitish Singh Jangwan, Mausin Khan, Richa Das, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Vinpocetine and Lactobacillus improve fatty liver in rats: role of adiponectin and gut microbiome
Ahmed M. El-Baz, Ahmed Shata, Nehal A. Nouh, et al.
AMB Express (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
In vivo identification of bioactive components of Poria cocos for adjusting mitochondria against metabolic dysfunction-associated fatty liver disease
Yanjuan Li, Pengquan Wang, Huan Yang, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e35645-e35645
Open Access | Times Cited: 2
Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds
Salvatore Pezzino, Maria Sofia, Chiara Mazzone, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e35498-e35498
Open Access | Times Cited: 2
Statin use and development and progression of non-alcohol fatty liver disease based on ultrasonography: a cohort study
Baoyu Feng, Fengde Li, Yanqi Lan, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 2
The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
Man-Qiu Mo, Zichun Huang, Yuzhen Liang, et al.
Digestive and Liver Disease (2021) Vol. 54, Iss. 4, pp. 461-468
Closed Access | Times Cited: 16
Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
Javier Ampuero, Rocío Gallego‐Durán, Douglas Maya‐Miles, et al.
Journal of Gastroenterology (2022) Vol. 57, Iss. 5, pp. 357-371
Open Access | Times Cited: 11
IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism
Yongqiang Ma, Guangshun Chen, Junfang Yi, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 11

Scroll to top